Researchers at the University of Pennsylvania have developed a unique chewing gum that significantly reduces levels of HPV and two bacterial species associated with head and neck cancer. This innovative treatment could complement existing therapies and offer a more accessible way to fight these infections.
- Reduces HPV by up to 93% in saliva samples
- Nearly eliminates two cancer-associated bacteria
- Targets harmful microbes while preserving healthy mouth flora
What happened
A research team led by Henry Daniell at the University of Pennsylvania crafted a chewing gum derived from lablab beans that includes FRIL, a natural antiviral protein. When tested on oral samples from patients with head and neck squamous cell carcinoma (HNSCC), the gum extract significantly lowered HPV levels by 93% and reduced bacteria linked to poor cancer outcomes.
The gum was further enhanced by adding protegrin, a peptide that kills harmful bacteria, effectively bringing levels of Porphyromonas gingivalis and Fusobacterium nucleatum close to zero in the tested samples. Crucially, this method did not harm beneficial oral bacteria, which are often negatively impacted by conventional treatments like radiation therapy.
Why it feels good
Head and neck cancer is notoriously aggressive, and existing treatments have struggled to improve long-term survival and quality of life significantly. The discovery of a chewing gum that can non-invasively target cancer-related microbes while protecting healthy bacteria brings hope for better, more tolerable therapies.
Moreover, the gum’s ease of use and potential affordability could make this approach accessible to broader populations, addressing a critical need for adjunct or preventive treatments in global healthcare, especially as oropharyngeal cancer rates linked to HPV continue to rise worldwide.
What to enjoy or watch next
The promising results published in Scientific Reports pave the way for clinical trials to test this chewing gum as a supplementary cancer therapy or as a preventive measure to reduce infection and transmission of cancer-associated microbes.
Future developments will focus on confirming safety and effectiveness in patients and exploring how this approach might integrate with existing treatments to improve patient outcomes, potentially transforming the standard care for cancers related to oral HPV and bacteria.